BioSpace News Archive

Wugen, Inc. today announced that management will participate in a fireside chat at 1:30 p.m. ET on Friday, September 30, 2022 at the upcoming Jefferies Cell & Genetic Medicine Summit set to take place in New York City.

Leuko, an MIT startup developing PointCheckTM, the first solution that enables at-home noninvasive white blood cell (WBC) monitoring, today announced a first closing of $5 million for their Series A round.

KSQ Therapeutics today named Micah Benson, PhD as the new Chief Scientific Officer (CSO) and announced the addition of a new Chief Technology Officer (CTO), Tom Leitch, to the KSQ leadership team.

ABVC Biopharma, Inc. today announced enrollment progress in the Phase II Part 2 clinical study of the Company’s ADHD medicine, ABV-1505, currently being conducted at five prestigious medical centers in Taiwan.

NanoVibronix UroShield Approved for Sale through NHS Internal Supply Chain Contract.

Evofem Biosciences (OTCPK: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,439,610, which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate).

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, announces that it is relaunching as LadRx Corporation.

Nucleus Biologics, The Cell Performance Company™, an industry-leading provider of small lot custom cell culture media, celebrated the opening of its newest building on their San Diego campus and the unveiling of additional state-of-the-art cleanrooms and infrastructure at a ribbon cutting ceremony on September 22.

Epiphany Technology Acquisition Corp. (the “Company”) announced today that the company’s Board of Directors (the “Board”) has approved an increase in the size of the Board from seven (7) directors to eleven (11) directors and elected Ross Haghighat, Stephen Sherwin, Ronald Eastman and Louis Lange as members of the Board.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.